Johnson & Johnson announced that it has entered into a definitive agreement to acquire Ambrx Biopharma, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger…
Isomorphic Labs announces strategic collaborations with two of the world’s leading pharmaceutical companies, Eli Lilly and Company and Novartis. Both collaborations are multi-target, focused on small molecules, and include a combination of upfront and milestone payments. These partnerships have the…
Novo Nordisk has entered into separate research collaborations with Omega and Cellarity. The Omega collaboration will leverage its proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity. The Cellarity collaboration aims to unravel novel biological drivers…
Eli Lilly and Company announced LillyDirect™, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes. LillyDirect will continue to be updated and expanded to improve the customer experience. “A complex U.S. healthcare system…
Merck Healthcare today announced a licensing agreement with Inspirna, Inc. for ompenaclid (RGX-202), a first-in-class oral inhibitor of the creatine transport channel SLC6A8, and SLC6A8-targeting follow-on compounds. Ompenaclid is currently being evaluated in a Phase II study for the second-line…
AbbVie and Umoja Biopharma, an early clinical-stage biotechnology company, today announced two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja’s proprietary VivoVecTM platform. The first agreement provides AbbVie an exclusive…
Suzhou Ribo Life Science Co., Ltd. and Ribocure Pharmaceuticals announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). The partnership brings together Ribo’s leading experience in the discovery and clinical development of…
Bristol Myers Squibb announced that the European Medicines Agency (EMA) has validated its marketing authorization application for the next-generation tyrosine kinase inhibitor (TKI) repotrectinib as a treatment for ROS1 TKI-naïve and -pretreated adult patients with ROS1-positive locally advanced or metastatic…
Voyager Therapeutics, a biotech company dedicated to advancing neurogenetic medicines, announced a strategic collaboration and capsid license agreement with Novartis Pharma, a subsidiary of Novartis to advance potential gene therapies for Huntington’s disease and spinal muscular atrophy. Voyager will provide…
Roche announced the entry into a definitive agreement to acquire select parts of the LumiraDx group related to LumiraDx’s innovative Point of Care technology. Following closing of the transaction, which is expected by mid-2024, the acquired entities will be fully…